Cowen: Tyler Van Buren Joins Cowen Equity Research Team to Cover Biotechnology


NEW YORK, 01 October 2021 (GLOBE NEWSLETTER) – Cowen inc. (NASDAQ: COWN) (“Cowen” or the “Company”) announced today that Tyler van buren joined the company’s equity research team to further expand the company’s coverage in the biotechnology sector. It will be based at new York and report to Robert Fagin, Cowen’s research director.

“We are delighted to welcome Tyler back to Cowen’s advanced healthcare research team,” said Mr. Fagin. “Our clients rely on Cowen’s leading biotechnology research to make informed investment decisions. We remain committed to expanding our research offerings and services.

Before joining Cowen, Mr. Van Buren was Managing Director and Senior Biotechnology Equity Research Analyst at Piper Sandler. Before Piper Sandler, Mr. Van Buren spent five years with Cowen’s biopharmaceutical research team. He holds a BS in Biochemistry and Cell Biology and an MS in Biology, both from University of California, San Diego.

Cowen’s acclaimed research department consists of 58 senior analysts spanning nearly 950 stocks across multiple industries including healthcare, consumer, energy, sustainability and energy transition, tech media, and telecommunications , capital goods and industrial products, and Washington Politics.

About Cowen Health Care Research

  • With 18 senior analysts, including seven dedicated to biotechnology, Cowen has one of the largest healthcare research footprints on Wall Street.
  • The team also includes two Cowen’s analysts Washington Research Group exclusively devoted to health policy. This effort complements and is integrated into the fundamental analysis of the company.
  • Cowen’s healthcare analysts are consistently ranked among the best in third-party polls, such as Institutional Investor magazine’s All-America research team and the Refinitiv StarMine Analyst Awards.
  • The team has a long tradition of collaboration and thought leadership. Renowned publications such as Cowen’s Biotech Quarterly, Therapeutics Categories and the Annual Drug Price Survey have been widely read and published regularly for over 25 years. Other prominent publications include Pharmaceutical Industry Pulse, Specialty Pharmaceutical Industry Pulse, and Life Science Tool Kit.
  • The research team also publishes numerous studies under Cowen’s flagship banner, Ahead of the Curve® Series. Recent reports have included extensive explorations of immuno-oncology, gene therapy, and respiratory syncytial virus (RSV).
  • The Company hosts some of the oldest and busiest events in the industry, including Cowen’s Healthcare Conference (now in his 42sd year); the Therapeutic conference (now in his 24e year); the MedTools Conference (now in his 10e year); and the FutureHealth Conference (now in his 7e year). Cowen also hosts many targeted events, including this year’s Cowen Gene Therapy Summit, the Oncology Innovation Summit, and the Psychedelics and New Mechanisms in Neuropsychiatry Summit.

About Cowen Inc.
Cowen inc. (“Cowen” or the “Company”) is a diversified financial services company that operates through two lines of business: a brokerage and an investment management division. The Broker and Broker Division of the Company provides investment banking, equity research, sales and trading, premier brokerage, global clearing and commission management services. Cowen’s investment management division builds on Cowen’s fundamental knowledge by developing differentiated and actively managed investment strategies that seek to meet the dynamic needs of our clients. Founded in 1918, the company is based in new York and has offices around the world. Learn more at


Gagnier CommunicationDan Gagnier[email protected]
646 569 5897

Main logo

Source: Cowen inc.

2021 GlobeNewswire, Inc., source Press Releases


About Author

Leave A Reply